C3-binding agents and methods of use thereof
AssigneeNGM Biopharmaceuticals, Inc.
InventorsDana Yen Mei Duey, Zhonghao Liu, Jie Tang, Yan Wang, Yiyuan Yin, Wenwu Zhai, Jared Martin Higbee
Life of this patent
Estimating the term…
Abstract
The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
Claims19
An isolated polynucleotide encoding an antibody that specifically binds human complement component C3 (SEQ ID NO:2), wherein the antibody comprises:
- a heavy chain variable region (VH) comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3 from the amino acid sequence set forth in SEQ ID NO:21, and
- a light chain variable region (VL) comprising VL CDR1, VL CDR2, and VL CDR3 from the amino acid sequence set forth in SEQ ID NO:25.
An isolated polynucleotide encoding an antibody that specifically binds human complement component C3 (SEQ ID NO:2), wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO:21 and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:25.
An isolated polynucleotide encoding an antibody that specifically binds human complement component C3 (SEQ ID NO:2), wherein the antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:29 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.
An isolated polynucleotide encoding an antibody that specifically binds human complement component C3 (SEQ ID NO:2), wherein the antibody comprises:
- (a) a VH comprising VH CDR1, VH CDR2, and VH CDR3 from the amino acid sequence set forth in SEQ ID NO:18, and a VL comprising VL CDR1, VL CDR2, and VL CDR3 from the amino acid sequence set forth in SEQ ID NO:19;
- (b) a VH comprising VH CDR1, VH CDR2, and VH CDR3 from the amino acid sequence set forth in SEQ ID NO:20, and a VL comprising VL CDR1, VL CDR2, and VL CDR3 from the amino acid sequence set forth in SEQ ID NO:25;
- (c) a VH comprising VH CDR1, VH CDR2, and VH CDR3 from the amino acid sequence set forth in SEQ ID NO:23, and a VL comprising VL CDR1, VL CDR2, and VL CDR3 from the amino acid sequence set forth in SEQ ID NO:25;
- (d) a VH comprising VH CDR1, VH CDR2, and VH CDR3 from the amino acid sequence set forth in SEQ ID NO:24, and a VL comprising VL CDR1, VL CDR2, and VL CDR3 from the amino acid sequence set forth in SEQ ID NO:25;
- or
- (e) a VH comprising VH CDR1, VH CDR2, and VH CDR3 from the amino acid sequence set forth in SEQ ID NO:22, and a VL comprising VL CDR1, VL CDR2, and VL CDR3 from the amino acid sequence set forth in SEQ ID NO:25.
Dependencies are inferred from the claim text.